Long-acting and extended-release opioid formulations
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.35 alerts
Get alerted when Policy 05.02.35 changes without checking for updates manually.
Monitor payer policy activity
Defines indications and limitations of use for several long-acting and extended-release opioid products for management of severe, chronic pain when alternatives are inadequate; applies to Wellmark/Blue Cross Blue Shield members covered under applicable contracts.
No material clinical or coverage changes in this revision.
Coverage Criteria for Long‑Acting and Extended‑Release Opioids
Product-specific coverage criteria
Covered when ALL of the following are met for each listed long-acting opioid product:
Applies to each product listed; see product labeling for specifics
Explicit limitation of use across listed products
Applies only to products with an opioid-tolerance requirement
Product-level indication and alternative-treatment requirement
Covered when ALL of the following are met for each listed product:
Applies to methadone oral solution, methadone tablets, morphine ER, MS Contin, Nucynta ER, OxyContin, oxymorphone ER, tramadol ER, Xtampza ER
Explicit requirement to reserve long-acting opioids
Not indicated as as-needed (prn)
Explicit limitation of use in each product's labeling
Methadone for opioid addiction — regulatory dispensing requirement
Regulatory requirement; failure to comply may result in sanctions
Covered with prior authorization
Covered when the following logical combinations are met:
Cancer/SCD/palliative/hospice cases provide an alternate coverage pathway
Required documentation/monitoring for chronic opioid therapy
Satisfies prior exposure requirement for ER initiation/continuation
Methadone for addiction is managed under OTP regulatory framework
Screenout logic (prescription benefit routing)
Automatic routing/payment under prescription benefit (not PA) when member meets recent diagnosis or claim indicators:
If any present, drug will be paid under the prescription benefit administered by CVS Caremark
Quantity-limited coverage
Coverage is limited to the product strengths, dosing frequencies, and supply quantities listed in the chart.
Examples include fentanyl transdermal patch counts per month/3 months and oral ER tablet counts corresponding to MME/day values
Initial quantity limit application
Apply initial quantity limits when patient is identified as non-cancer/non-SCD/non-palliative/hospice and meets prior opioid exposure criteria.
If not met, claim rejects and PA is required
Post-limit and chronic pain approval
Coverage for amounts above initial limits and for chronic pain:
Methadone for addiction is excluded from these limits
These long-acting and extended-release opioid products are intended for management of severe, chronic pain requiring daily, around-the-clock, long-term opioid treatment and should be reserved for patients for whom alternative treatment options (e.g., non‑opioid analgesics or immediate‑release opioids) are ineffective, not tolerated, or otherwise inadequate. The product labeling and this policy consistently state that these formulations are not indicated for as‑needed (PRN) analgesia. Prescribers should follow product-specific limitations of use and ensure that ER/LA formulations are used only when clearly indicated and appropriate monitoring and reassessment plans are in place.
The policy emphasizes that long-acting and extended-release opioid products must be reserved for patients who have failed or cannot tolerate alternative therapies. Use of these products when adequate alternatives exist is inconsistent with the clinical intent and may be considered not medically necessary. Prior authorization and step‑therapy checks are used to confirm that alternatives were considered or tried before approving ER/LA opioid therapy.
Methadone used for opioid addiction (detoxification or maintenance) must be dispensed through a federally certified Opioid Treatment Program (OTP) per 42 CFR Part 8; this policy excludes such OTP‑dispensed addiction treatment from the ER opioid limits. Short exceptions to the OTP certification requirement apply during inpatient care for non‑addiction primary admissions and during emergency periods of up to 3 days while definitive addiction care is sought, consistent with regulatory provisions.
Xtampza ER is specifically identified in labeling and the clinical rationale as intended for daily, around‑the‑clock, long‑term management of severe pain and is not indicated for as‑needed (PRN) use. Requests to use Xtampza ER as intermittent or PRN therapy are inconsistent with labeled indications and this policy.
Certain product strengths or chart entries are listed with a marker of 0*** in the Opioid Analgesics ER Quantity Limits Chart. These 0*** strengths are effectively excluded or blocked for the associated supply intervals and quantity limits; requests for those specific strengths are likely to be denied or will require special justification and prior authorization.
Members with cancer, sickle cell disease, or those receiving palliative or hospice care are routed to an alternate prescription benefit pathway and are not subject to the step‑therapy and post‑limit restrictions under this ER/LA opioid policy. Routing is determined by recent claims or member profile indicators (e.g., cancer or SCD drug claims, relevant ICD‑10 diagnoses, or hospice residence codes within the past 365 days), and such claims will be paid under the prescription benefit administered by CVS Caremark.
Methadone dispensed for addiction treatment in certified OTPs is excluded from the ER opioid quantity limits and administrative rules in this policy. OTP‑dispensed methadone must meet SAMHSA and state certification requirements and Federal Opioid Treatment Standards (42 CFR 8.12); methadone used for addiction is managed under those regulations rather than the ER opioid limits described here.
Use of ER/LA opioid formulations for PRN or intermittent/as‑needed analgesia, or prescribing them when adequate alternative treatments exist, is inconsistent with the intent of this policy and with product labeling. The CDC guideline and this policy both advise reserving ER/LA opioids for continuous severe pain after appropriate trials of alternatives; prescribing for PRN use or when alternatives suffice may be denied or deemed not medically necessary.
Prescribing ER/LA opioids as PRN or when alternatives are adequate poses clinical and regulatory risk: it departs from labeled indications, increases the risk of misuse, and may be considered off‑label or inappropriate. Providers should document why long‑acting therapy is necessary, demonstrate prior trials of alternatives, and ensure monitoring per the policy to mitigate these risks.
Initiating ER/LA opioids for acute pain, without prior adequate exposure to immediate‑release opioids, or for intermittent/as‑needed use is not consistent with the CDC guidance or this policy. The policy requires evidence of prior opioid exposure (e.g., ≥ an 8‑day supply of an immediate‑release opioid in the past 90 days or ≥ a 30‑day supply of an ER opioid in the past 90 days) before initial ER dispensing without prior authorization; initiation for acute or short‑term pain should use short‑acting agents instead.
Coding and MME Thresholds
| No codes listed |
| No codes listed |
Provider Actions, Prior Authorization, and Documentation
Benefit verification and PA may be required
Verify member benefits and contract language at the time of service. Prior authorization (PA) may be required depending on the member's plan and contract exclusions; Wellmark (Blue Cross Blue Shield - Iowa) will only determine medical necessity if the benefit exists.
- Check individual member benefits and contract at time of service
- PA may be required per plan
Prior authorization for ER starts and higher MME
Claims for initiating certain extended-release (ER) or long-acting opioids or for requests that would result in higher morphine milliequivalent (MME) daily doses will be subject to prior authorization. Specifically, claims will reject and require PA when the member lacks qualifying recent IR or ER opioid prescription history (see Initial-use PA trigger) or when the requested quantity exceeds established quantity limits corresponding to ~90 MME/day initial limits or up to 200 MME/day post-limit.
- PA required when no qualifying IR (≥8 days) or ER (≥30 days) history in past 90 days
- PA required for quantities exceeding initial quantity limits (~≤90 MME/day) or post limits (≤200 MME/day)
Quantity limits govern prior authorization
Coverage for extended-release opioids is governed by quantity limits specified per product strength and supply interval. Requests exceeding the charted monthly or 3-month quantities (per the Opioid Analgesics ER Quantity Limits Chart) will be rejected and require prior authorization.
- Quantity limits accumulate across drugs with same unit limits
- Chart lists Column A (initial 1 month), Column B (initial 3 month), Column C/D (post 1 month/3 month) limits
When prior authorization is required
A prior authorization is required when initiating an ER/LA opioid for a patient without the required recent opioid history or when the requested quantity exceeds the initial or post limits in the quantity chart. The PA review will apply clinical criteria, documentation, and any applicable exceptions.
- PA required for initiation if no 8-day IR or 30-day ER history in past 90 days
- PA required for requests exceeding initial quantity limits corresponding to ≤90 MME/day
Conservative step requirement and inappropriate-use risk
ER/LA opioids should be reserved for patients for whom non-opioid therapies or immediate-release opioids are ineffective or not tolerated. Inappropriate or off-label use (including PRN use or starting ER/LA opioids in opioid-naïve patients without stepping through IR options) may lead to denial.
- Reserve ER/LA opioids until non-opioid or IR options are ineffective or not tolerated
- ER/LA opioids are not indicated as as‑needed (PRN) analgesics
Screening, exceptions, and PA triggers
Claims will be screened for recent cancer, sickle cell disease, palliative, hospice indicators, or related medication fills. If such indicators exist (claims, diagnosis codes, or member profile history), step therapy and post-limit quantity restrictions do not apply and the drug may be paid under the prescription benefit without PA per the screenout logic.
- Screen for cancer, sickle cell disease, palliative/hospice diagnosis codes in claims or member profile (past 365 days)
- Screen for 1‑day cancer/SCD drug fill in past 365 days or hospice residence code
Restricted strengths
Some strengths are restricted or marked as '0***' in the quantity limits chart; requests for these restricted strengths may be denied or require special review.
- Review chart for '0***' strengths which may be restricted
- Requests for restricted strengths could be denied
Initial-use prior authorization trigger and claim history requirements
To avoid automatic rejection, document prescription claim history demonstrating prior use: at least an 8-day supply of an immediate‑release (IR) opioid in the past 90 days OR at least a 30‑day supply of an ER opioid in the past 90 days. If neither is present, the claim will reject with a PA requirement.
- Document recent claim history: ≥8 days IR fill in past 90 days OR ≥30 days ER fill in past 90 days
- Absent qualifying history, submit PA for review
Quantity limit prior authorization trigger
When requested quantities exceed the initial quantity limits (set to encompass typical starting dosages ~≤90 MME/day), the system will reject and require PA. Prior authorization may permit coverage up to the post-limit thresholds (≤200 MME/day) if clinical criteria are met; requests beyond charted post limits are subject to denial.
- Initial limits correspond to ≤90 MME/day (per 25 days)
- Post limits may allow up to ≤200 MME/day (per 25 days) with PA; quantities beyond charted post limits are subject to denial
Monitoring and reassessment requirements
Document clinical monitoring, reassessment, and safety: confirm the patient can safely take the requested dose, plan for regular monitoring for opioid use disorder, reassess pain and function within the first month after initiation or dose increase and at least every 3 months thereafter, and document that titration to higher doses is reserved for patients who clearly benefit and for whom risks are justified.
- Document plan for regular monitoring and reassessment (first month after start or dose increase, then ≥ every 3 months)
- Document that benefits outweigh risks before titrating to higher doses
Claim history and diagnosis documentation
Provide supporting documentation with PA requests: recent prescription claim history, relevant ICD-10 diagnosis codes (including cancer, sickle cell disease, palliative/hospice as applicable), clinical rationale for ER/LA opioid use, and monitoring/reassessment plans.
- Include claim history demonstrating prior IR/ER use when applicable
- Include ICD-10 codes and clinical justification for ER/LA opioid therapy
Billing and coding requirements
Report provider services using appropriate billing codes. Use correct CPT, HCPCS (alpha numeric), revenue, and ICD diagnostic codes when submitting claims and prior authorization requests; failure to use appropriate codes may lead to incorrect billing or denial.
- Use appropriate CPT, HCPCS, Revenue, and ICD-10 codes on claims and PA submissions
- Ensure coding matches the services and diagnoses documented
Step Therapy and Prior Opioid Exposure Requirements
Trial of alternative treatments required before initiating long-acting formulations
Conservative step requirement applied before initiating long‑acting formulations
Trial of alternatives required (nonopioid or immediate-release opioid) before initiating ER/LA opioids
Policy emphasizes reserving ER/LA opioids until alternatives fail or are not tolerated
Document prior opioid use history per step therapy rules — IR trial and ER stability
This documentation determines whether initial quantity limits apply or PA is required
Prior immediate-release opioid exposure (8-day supply in past 90 days) or prior ER opioid stability (30-day supply in past 90 days) for initial ER prescribing without PA
If not met, claim will reject and require prior authorization
Quantity and Dispensing Frequency Limits
No imaging required for ER opioid prescribing
No imaging requirements are stated for ER opioid prescribing in this policy segment.
Definitions Used in This Policy
Background
Background: this document defines indications and administrative limits for multiple long‑acting and extended‑release opioid products. The criteria align coverage with product labeling, FDA guidance, and clinical practice recommendations, reserving ER/LA opioids for continuous severe chronic pain when alternatives are inadequate and emphasizing monitoring, reassessment, and quantity limits to reduce risks of addiction, misuse, and overdose.
Not Covered / Explicit Exclusions
Not covered: Use of Xtampza ER as an as‑needed (PRN) analgesic is explicitly not indicated and is therefore not covered under this policy. Additionally, specific strengths or formulations marked 0*** in the Opioid Analgesics ER Quantity Limits Chart are restricted or unavailable and will not be covered without appropriate justification or prior authorization.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.